New drug for trichomoniasis treatment
The FDA has approved an application to expand the therapeutic indications for the drug SOLOSEC (secnidazole). Secnidazole is a broad-spectrum antimicrobial and antiprotozoal agent.
Based on this, the product, produced by Indian company, becomes the only single-dose treatment option for trichomoniasis and bacterial vaginosis in the United States. This will help to eliminate the problems associated with the treatment compliance, thereby reducing the risk of pelvic inflammatory disease and sexually transmitted infections.
This conclusion is based on the results of a study in patients with trichomoniasis. The study has demonstrated a fairly significant effectiveness of SOLOSEC: 92.2% compared with placebo. During the study, no serious adverse events were observed. The most common side effects were vulvovaginal candidiasis and nausea.